Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

5.98USD
9:00pm BST
Change (% chg)

$-0.02 (-0.33%)
Prev Close
$6.00
Open
$6.01
Day's High
$6.01
Day's Low
$5.88
Volume
8,082
Avg. Vol
13,240
52-wk High
$10.51
52-wk Low
$3.35

Latest Key Developments (Source: Significant Developments)

Merrimack Pharmaceuticals Discontinues Development Of MM-310
Thursday, 4 Apr 2019 

April 4 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK DISCONTINUES DEVELOPMENT OF MM-310.MERRIMACK PHARMACEUTICALS INC - EXPECTS TO REDUCE WORKFORCE.MERRIMACK PHARMACEUTICALS INC - CONTINUES TO PRUDENTLY ADVANCE PROGRAMS WHILE COMPLETING ASSESSMENT OF ITS STRATEGIC ALTERNATIVES.MERRIMACK PHARMACEUTICALS INC - CONCLUDED THAT STUDY WOULD NOT BE ABLE TO REACH AN OPTIMAL THERAPEUTIC INDEX FOR MM-310.MERRIMACK PHARMACEUTICALS INC - NARROWED SCOPE OF PIPELINE TO MM-401 AND MM-201; INITIATING STEPS TO CLOSE OUT REMAINING CLINICAL ACTIVITIES.MERRIMACK PHARMACEUTICALS INC - SAFETY UPDATE SHOWS PHASE 1 STUDY UNABLE TO REACH OPTIMAL THERAPEUTIC INDEX FOR MM-310.MERRIMACK - PHASE 1 STUDY UNABLE TO REACH OPTIMAL THERAPEUTIC INDEX FOR MM-310 DUE TO CONTINUED OBSERVATION OF CUMULATIVE PERIPHERAL NEUROPATHY.  Full Article

JFL Partners Nominates 4 People For Election To Merrimack Pharmaceuticals' Board
Thursday, 14 Mar 2019 

March 14 (Reuters) - Merrimack Pharmaceuticals Inc ::JFL PARTNERS SAYS ON MARCH 13, DELIVERED LETTER TO MERRIMACK PHARMACEUTICALS - SEC FILING.JFL PARTNERS SAYS NOMINATING JASON ARYEH, ARON ENGLISH, JOSEPH LAWLER AND KENNETH LIN, FOR ELECTION TO MERRIMACK PHARMACEUTICALS' BOARD.  Full Article

Merrimack Reports Q4 Loss Per Share $0.97
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.97.MERRIMACK PHARMACEUTICALS - BELIEVES CASH, CASH EQUIVALENTS, OTHERS OF $71.3 MILLION AS OF DEC 31, 2018 TO FUND ITS OPERATIONS INTO AT LEAST H2 2022.  Full Article

Merrimack Pharmaceuticals - Expects to have about 27 employees after corporate restructuring - SEC filing
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS - EXPECTS TO HAVE ABOUT 27 EMPLOYEES AFTER CORPORATE RESTRUCTURING - SEC FILING.MERRIMACK PHARMACEUTICALS - TO INCUR EXPENSES RELATED TO RESTRUCTURING OF ABOUT $1.5 MILLION TO $1.8 MILLION FOR EMPLOYEE SEVERANCE, BENEFITS & RELATED COSTS.  Full Article

Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER DUE TO FUTILITY.MERRIMACK PHARMACEUTICALS INC - MM-121 DID NOT IMPROVE PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC).MERRIMACK PHARMACEUTICALS INC - IMPLEMENTING A COMPREHENSIVE REVIEW OF ITS DRUG CANDIDATE PIPELINE.MERRIMACK PHARMACEUTICALS INC - DECISION HAS BEEN MADE TO TERMINATE STUDY..MERRIMACK PHARMACEUTICALS INC - FUTILITY WAS OBSERVED, DECISION HAS BEEN MADE TO TERMINATE STUDY.MERRIMACK - DECISION WAS MADE FOLLOWING ANALYSIS THAT WAS TRIGGERED BY OCCURRENCE OF 75% OF EVENTS REQUIRED FOR TRIAL COMPLETION.MERRIMACK PHARMACEUTICALS INC - DECISION WAS MADE IN AGREEMENT WITH CHAIR OF INDEPENDENT DATA SAFETY MONITORING BOARD.MERRIMACK PHARMACEUTICALS INC - MM-121 IS ALSO CURRENTLY BEING EVALUATED IN SHERBOC STUDY.  Full Article

Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141
Monday, 25 Jun 2018 

June 25 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK ANNOUNCES TOP-LINE RESULTS FROM RANDOMIZED PHASE 2 TRIAL OF MM-141 IN FRONT-LINE METASTATIC PANCREATIC CANCER.MERRIMACK PHARMACEUTICALS INC - COMPANY CEASES DEVELOPMENT OF MM-141.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS -.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS.MERRIMACK PHARMACEUTICALS INC - CARRIE STUDY RESULTS WERE CONSISTENT IN ALL SUBGROUPS ANALYZED.  Full Article

Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Merrimack reports Q3 loss per share from continuing operations $0.40
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack reports third quarter 2017 financial results.Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40.Merrimack Pharmaceuticals-Believes unrestricted cash & cash equivalents & payments from shire will be sufficient to fund operations into H2 2019.  Full Article

Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer.Merrimack Pharmaceuticals - ‍orphan drug designation by FDA includes eligibility for 7-year period of marketing exclusivity for MM-121 upon approval​.Merrimack Pharmaceuticals - ‍MM-121 is currently being evaluated in SHERLOC study; top-line data for SHERLOC study is expected in H2 2018​.  Full Article

Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Merrimack Pharmaceuticals Inc ::Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020.Merrimack Pharmaceuticals-commenced tender offer to buy $25.03 million aggregate principal amount of outstanding 4.50 pct convertible senior notes due 2020​.  Full Article